IN8bio, Inc. reported financial results for the second quarter ended June 30, 2026, on August 6, 2026. The company reported a net loss of $4.8 million, or $0.25 per share, compared to a net loss of $5.1 million in the prior year period. Cash and cash equivalents stood at $18.0 million as of June 30, 2026. Research and development expenses were $2.5 million, while general and administrative expenses decreased to $2.4 million from $2.7 million in the comparable prior year period. Clinically, IN8bio presented updated data at ASCO 2026 showing median overall survival exceeding 19.5 months for glioblastoma patients treated with DeltEx™ Drug Resistant Immunotherapy (DRI). The company also advanced its gamma-delta T cell engager platform, moving the CD19-targeting candidate INB-619 into IND-enabling studies and expecting initial in vivo data in the second half of 2026. IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies and engagers for cancer and autoimmune diseases.